tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

GB:AVCT Stock Latest News

Avacta Settles Bond Payment in Cash, On Track for 2024 Goals
Company AnnouncementsAvacta Settles Bond Payment in Cash, On Track for 2024 Goals
7d ago
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
PremiumPress Releases
Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors
17d ago
Avacta Group’s AGM Success and Clinical Advances
PremiumCompany Announcements
Avacta Group’s AGM Success and Clinical Advances
29d ago
Avacta Advances Cancer Drug Trial, Strengthens Board
PremiumCompany Announcements
Avacta Advances Cancer Drug Trial, Strengthens Board
29d ago
Avacta Group Appoints New Chairman, Eyes Growth
PremiumCompany Announcements
Avacta Group Appoints New Chairman, Eyes Growth
1M ago
Avacta Engages Peel Hunt as New Adviser
PremiumCompany AnnouncementsAvacta Engages Peel Hunt as New Adviser
1M ago
Avacta Group Announces AGM and Yearly Report
PremiumCompany Announcements
Avacta Group Announces AGM and Yearly Report
2M ago
Avacta Advances Oncology Program with AVA6000 Trial
PremiumCompany Announcements
Avacta Advances Oncology Program with AVA6000 Trial
2M ago
Avacta Group Advances with Strong 2023 Performance
PremiumCompany Announcements
Avacta Group Advances with Strong 2023 Performance
3M ago
Avacta Appoints New CEO to Advance Cancer Treatments
PremiumCompany Announcements
Avacta Appoints New CEO to Advance Cancer Treatments
3M ago
Avacta Group Announces New Share Listing
PremiumCompany Announcements
Avacta Group Announces New Share Listing
3M ago
Avacta Group Announces Upcoming Financial Results
PremiumCompany Announcements
Avacta Group Announces Upcoming Financial Results
3M ago
Avacta Group Issues Shares to Settle Debt
PremiumCompany AnnouncementsAvacta Group Issues Shares to Settle Debt
3M ago
Avacta Group – AVA6000 Abstract Release by AACR and Full Presentation Update
PremiumPress Releases
Avacta Group – AVA6000 Abstract Release by AACR and Full Presentation Update
4M ago
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
PremiumPress Releases
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
5M ago
Appointment of Chief Business Officer
PremiumPress Releases
Appointment of Chief Business Officer
7M ago
ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
PremiumPress Releases
ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
8M ago
Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PremiumPress Releases
Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >